Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

PURPOSE: Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options. Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of transcription pathway in the pathogenesis and clinical course of pancreatic cancer. PATIEN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Hurwitz, Herbert I., Uppal, Nikhil, Wagner, Stephanie A., Bendell, Johanna C., Beck, J. Thaddeus, Wade, Seaborn M., Nemunaitis, John J., Stella, Philip J., Pipas, J. Marc, Wainberg, Zev A., Manges, Robert, Garrett, William M., Hunter, Deborah S., Clark, Jason, Leopold, Lance, Sandor, Victor, Levy, Richard S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089161/
https://ncbi.nlm.nih.gov/pubmed/26351344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.4578
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados